Keyword: Mitsubishi Tanabe Pharma
The Bausch Health subsidiary plans to trial the ex-Biogen S1P receptor functional antagonist in ulcerative colitis.
Though the Japanese data aren’t a perfect predictor for vadadustat’s global registrational studies, Piper Jaffray analysts called them “a nice proxy."
The partnership focuses on cutting the time spent searching and collecting information from medical papers and ClinicalTrials.gov.
The company framed the decision as mutual and motivated by a desire to install a leader with more scientific experience.
Mitsubishi Tanabe is to spend $1.1 billion on Parkinson’s disease biotech NeuroDerm as it looks to boost its U.S. presence and CNS pipeline.
Clinigen has signed exclusive agreements with Mitsubishi Tanabe, Shionogi and Romark to cooperate on expanded access to their medicines.
Vifor Pharma has struck a deal to sell Akebia Therapeutics’ phase 3 oral anemia drug vadadustat through its network of U.S. dialysis centers.
Otsuka Pharmaceutical has expanded its anemia pact with Akebia Therapeutics.
GlaxoSmithKline has one of the lowest R&D budgets in percentage of revenue terms of its peers; although its research budget was slightly up on 2015, this is still markedly down from the around £4 billion it was spending in 2012-13.